C4531001

The Pfizer Clinical Research Unit Brussels is conducting a study for the treatment of atopic dermatitis (AD).

Card Summary Component

Who may participate

This study is seeking healthy male and female participants, meaning that the participants will not have the condition being studied.

In addition to the criteria listed, participants must meet the following requirements:

  • Have a minimum body weight of 50 kg
  • Have body Mass Index of 17.5 - 32 kg/m2
  • Be a non-smoker or a smoker who smokes a maximum of 5 cigarettes per day
  • Be able to meet all study visit requirements

There are other requirements for participation in this study. The study staff will explain these to you during the screening process.

Condition

Healthy

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Age

18-65 years

The age a person must be to participate in a clinical trial.

Sex

Male and Female

The sex of people who may participate in a clinical trial. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

The study is planned to last for approximately 569 days. There are several examinations procedures required in connection with the study:

  • A screening examination during which you will sign a COVID ICD and the study ICD
  • 1 dosing period of 5* overnight stays at the PCRU. You will not be able to leave the PCRU during that time
  • 11 planned follow-up visits
Required overnight stays

5 nights

A participant may be required to stay overnight at the PCRU for observation and study procedures. The number and length of overnight stays is determined by the design of the study.

How long is the study?

569 days

The length of the study includes the time from screening until the final follow-up call or study activity. There may be up to 28 days between screening and dosing.

Compensation

11 295€ + 150€

Participants in clinical trials at the PCRU receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.

All of the study procedures will be clearly explained to you during screening and can be viewed by downloading the informed consent form.